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Abstract
Purpose—African American (AA) women are more likely than white women to be obese and to 
be diagnosed with ER- and triple negative (TN) breast cancer, but few studies have evaluated the 
impact of obesity and body fat distribution on breast cancer subtypes in AA women. We evaluated 
these associations in the AMBER Consortium by pooling data from four large studies.
Methods—Cases were categorized according to hormone receptor status as ER+, ER-, and TN 
(ER-, PR-, and HER2-) based on pathology data. A total of 2,104 ER+ cases, 1,070 ER- cases 
(including 491 TN cases), and 12,060 controls were included. Odds ratios (OR) and 95% 
confidence intervals (CI) were computed using logistic regression, taking into account breast 
cancer risk factors.
Results—In postmenopausal women, higher recent (most proximal value to diagnosis/index 
date) BMI was associated with increased risk of ER+ cancer (OR: 1.31; 95% CI: 1.02–1.67 for 
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BMI≥35 vs <25 kg/m2) and with decreased risk of TN tumors (OR: 0.60; 95% CI: 0.39–0.93 for 
BMI≥35 vs. <25). High young adult BMI was associated with decreased premenopausal ER+ 
cancer and all subtypes of postmenopausal cancer, and high recent waist-to-hip ratio (WHR) with 
increased risk of pre-menopausal ER+ tumors (OR: 1.35; 95% CI: 1.01–1.80) and all tumor 
subtypes combined in postmenopausal women (OR: 1.26; 95% CI: 1.02–1.56).
Conclusions—The impact of general and central obesity varies by menopausal status and 
hormone receptor subtype in AA women. Our findings imply different mechanisms for 
associations of adiposity with TN and ER+ breast cancers.
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INTRODUCTION
Breast cancer is a heterogeneous disease, with growing evidence that the various subtypes 
may have different etiologies [1,2]. African American (AA) women are more likely to 
develop estrogen receptor (ER) negative tumors including the subset of ER- tumors that are 
also lacking expression of progesterone receptor (PR-) and human epidermal growth factor 
receptor 2 (HER2-), known as triple negative (TN) breast cancer [3]. Both ER- and TN 
tumors tend to be more aggressive and have worse prognosis [3].
Obesity is currently a global public health concern, which disproportionately affects AA 
women in the United States. The prevalence of obesity (BMI≥30 kg/m2) is 58.6% among 
AA women compared to 33.4% of non-Hispanic white women [4]. AA women more often 
have a fat distribution pattern consistent with central obesity [5], which has been associated 
with hyperinsulinemia and insulin resistance, in turn implicated in breast carcinogenesis [6]. 
In the majority of studies, mostly conducted in white women, obesity is associated with 
increased risk of postmenopausal and decreased risk of premenopausal breast cancer [7]. A 
few of those studies considered effects of obesity by hormone receptor subtypes: most 
suggest a stronger association of obesity with ER+ tumors, while the associations for ER- 
and TN breast cancers remain unresolved [8]. The few studies in AA women have had 
inconsistent results [9]. In view of the high prevalence of obesity and ER- tumors in AA 
women, informative data are clearly needed.
We examined general and central obesity and breast cancer subtypes in AA women 
participating in the AMBER (African American Breast Cancer Epidemiology and Risk) 
Consortium.
MATERIALS AND METHODS
The AMBER Consortium is a collaboration of four studies, the Carolina Breast Cancer 
Study (CBCS), the Women’s Circle of Health Study (WCHS), the Black Women’s Health 
Study (BWHS), and the Multiethnic Cohort Study (MEC) [10,11].
CBCS is a population-based case-control study of breast cancer [12]; cases were identified 
through the North Carolina Central Cancer Registry by rapid case ascertainment, with 
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oversampling of younger cases. Controls were identified through the Division of Motor 
Vehicles for women under 65 years and Health Care Financing Administration for women 
65 or older, and were frequency matched to cases on age (±5 years) and race. Home 
interviews were conducted to collect information on breast cancer risk factors, as well as 
height and weight one year before diagnosis and weight at age 18 years, and to conduct 
anthropometric measurements (height, weight and waist and hip circumferences) [13,14]. 
Average time between diagnosis and the interview was 3–6 months.
WCHS is a case-control study of breast cancer [15,16], originally recruiting white and AA 
women in New York City (NYC) and New Jersey (NJ), with recruitment currently limited to 
AA women in ten counties in NJ. In NYC, cases were identified through hospitals with large 
enrollments of AA women; controls were recruited through random digit dialing (RDD), 
frequency matched to cases by age and race. In NJ cases are identified by rapid case 
ascertainment conducted by the NJ State Cancer Registry. Controls were initially identified 
by RDD, later complemented for the AA group with community-based recruitment [16]. 
During in-person home interviews information was collected on breast cancer risk factors, 
including height, and weight at age 20 years and 1 year before diagnosis/interview [17]. 
Anthropometric measurements were taken during the home interview using a standardized 
protocol [18]. Interviews, on average, took place approximately nine months after diagnosis.
BWHS is a prospective study among AA women across the United States [19]. The study 
was established in 1995, with 59,000 AA women responding to a 14-page health 
questionnaire. Biennial follow-up questionnaires update covariates and ascertain new cases 
of breast cancer. Cases are confirmed with medical records and cancer registry data. 
Information collected included demographic factors, family history of breast cancer, 
reproductive and medical history, hormone use, current weight and weight at age 18, height, 
and waist and hip circumferences [20].
MEC is a prospective study that includes 16,594 AA women [21]. The cohort, started in 
1993–1996, is comprised of respondents to a 26-page questionnaire mailed to subjects 
identified through driver’s license files for the state of Hawaii and Los Angeles County in 
California, supplemented by other sources. Cases were identified by linkage to the Hawaii 
Tumor Registry, the Cancer Surveillance Program for Los Angeles County and the 
California State Cancer Registry. Follow-up questionnaires, sent approximately every five 
years collect information on demographics, medical and reproductive histories and other 
cancer risk factors, including current height and weight, weight at age 21 years [22], and 
waist and hip circumferences [23]. Given the few premenopausal participants, MEC was 
only included in analyses of postmenopausal women.
For both BWHS and MEC, a nested case-control approach was used to pool data with the 
other two studies. Controls were frequency matched to cases on 5-year age category and 
questionnaire completed prior to case diagnosis (index date).
Women were considered postmenopausal if their periods had stopped because of natural 
menopause or bilateral oophorectomy. Women who reported a hysterectomy but retained 
one or both ovaries were classified as premenopausal if their current age was less than the 
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10th percentile of age at natural menopause (<43 years), as postmenopausal if their age was 
greater than the 90th percentile of age at natural menopause (>56 years), and as having 
unknown menopausal status if their age was 43–56 years.
Pathology data from hospital records or cancer registries were used to classify cancers by 
subtype based on ER, PR and HER2. Pooled data from the four studies after exclusion of 
subjects with missing values for menopausal status, BMI, and ER receptor status, resulted in 
an analytical dataset with 2,104 ER+ cases, 1,070 ER- cases (which included 491 TN cases), 
and 12,060 controls. Data on waist and hip circumferences were available on 2,461 cases 
and 8,269 controls. Each study was approved by the individual Institutional Review Boards 
at participating institutions.
Statistical Analyses
Questionnaire data from the four studies were pooled and harmonized in the AMBER 
Biostatistics and Data Management Core, as described in detail elsewhere [10]. In brief, 
variables of interest for analyses were identified and, if categorical, categories specified. 
Individual studies carried out cleaning and recoding of their data, and returned to the Core 
for final quality checks and harmonization. Recent BMI and WHR were based on 
anthropometric data prior and closest to diagnosis/index date (for most women, 
approximately one year). Because height, weight, waist and hip measurements were 
continuous variables, no re-categorization was needed. Young adult BMI was based on self-
reported weight at age 18 (BWHS and CBCS), 20 (WCHS), or 21 (MEC). All analyses were 
stratified by menopausal status. Body mass index (BMI) was computed as weight in 
kilograms (kg) divided by the square of height in meters (m). Waist-to-hip ratio (WHR) was 
computed as waist circumference (inches) divided by hip circumference (inches). Recent 
BMI was categorized according to the World Health Organization (WHO) International 
Classification. Because a large proportion of participants had a BMI below 25 as young 
adults (age 18–21 years), that category was further divided into BMI<20 and 20–24.9. 
Quartiles were used for WHR, with cutpoints based on the distribution of all controls 
combined. The same cutpoints were used for pre- and postmenopausal women to be able to 
compare estimates across menopausal status.
Odds ratios (OR) and 95% confidence intervals (CI) for ER+ and ER- tumors vs. controls 
were computed using polytomous logistic regression. Binary logistic regression was used to 
compute OR and CIs for overall breast cancer and TN breast cancer vs. controls. 
Multivariable models included as covariates age, education, study, time period of enrollment 
(1993–98, 1999–2005, 2006–2013), geographical region (South, Midwest, West, New 
Jersey, other Northeast), family history of breast cancer, age at menarche, parity, 
breastfeeding (yes/no), age at first birth, duration of oral contraceptive use, hormone therapy 
(HT) use, and age at menopause (for postmenopausal women). BMI and young adult BMI 
were further adjusted for WHR, and WHR was further adjusted for current BMI to assess 
potential independent effects of general and central adiposity. We also evaluated the joint 
effects of recent BMI and young adult BMI by modeling the two variables with low recent 
BMI (<25) and low young adult BMI (lowest tertile) as the reference category in separate 
models for ER+ and ER- cases compared to all controls. Similar joint analyses were 
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conducted for recent BMI and WHR. P values for trend were computed by including the 
median in each quartile as a continuous variable in regression models. Analyses in 
postmenopausal women were repeated after excluding HT users to assess possible effect 
modification. Analyses were conducted using SAS version 9.2 (SAS Institute, Cary NC).
RESULTS
Selected characteristics of the AMBER studies are shown in Table 1. CBCS oversampled 
younger AA women and had a higher proportion of cases younger than 40 years. Consistent 
with national trends [1], the younger CBCS population had higher proportions of ER-and 
TN breast cancers compared to the other studies. MEC had the highest proportion of older 
women (≥60 years). The prevalence of obesity (BMI≥30) was higher in CBCS and WCHS, 
and WCHS, CBCS and MEC subjects had higher prevalence of central obesity (WHR>0.8) 
than BWHS participants.
As shown in Table 2, recent BMI was not significantly associated with premenopausal ER+, 
ER-, or TN cancer. For postmenopausal women, high recent BMI was associated with 
increased risk of ER+ cancer (OR= 1.31, 95% CI 1.02–1.67) and with reduced risk of TN 
disease (OR=0.60, 95% CI 0.39–0.93).
Regarding BMI as a young adult (Table 3), in premenopausal women, higher BMI was 
associated with reduced risk of ER+ breast cancer (OR: 0.65; 95% CI: 0.42–1.01 for BMI 
≥30 vs <20), with no associations with ER- or TN cancer. In contrast, there was a suggestion 
that a higher young adult BMI was associated with reduced risk of postmenopausal breast 
cancer (overall and for each subtype), although most risk estimates were not statistically 
significant.
Higher WHR (Table 4) was associated with increased risk of ER+ cancer (OR: 1.35, 95% CI 
1.01–1.80 for WHR >0.88 vs. ≤0.64) and with non-significant increases of ER- and TN 
cancer among premenopausal women. Among postmenopausal women, there was elevated 
risk with higher WHR for each subtype, with stronger risk for TN breast cancer (OR: 1.73; 
95% CI 1.02–2.91 and 1.60; 95% CI: 0.94–2.73 for third and fourth quartiles, respectively, 
compared to lowest). When analyses were repeated in postmenopausal women excluding 
hormone therapy users, results did not substantially change (data not shown).
In joint effects analyses for recent and young adult BMI (Table 5), there were no clear 
patterns and no significant associations with ER+ or ER- breast cancer among 
premenopausal women. Among postmenopausal women, those who were thin as young 
adults (BMI<19.48, lowest tertile), but had a high recent BMI (≥35) had almost double the 
risk of ER+ breast cancer (OR: 1.91; 95% CI 1.32–2.75, p for interaction: 0.08), compared 
with women with low recent and young adult BMI. Moreover, being heavy as an adult was 
associated with reduced risk of postmenopausal ER- cancer regardless of young adult BMI.
DISCUSSION
There are several major findings from this largest study, to date, evaluating anthropometric 
factors and breast cancer subtypes in AA women.. Among postmenopausal women, higher 
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recent BMI was associated with increased risk of ER+ cancer, and the risk was even greater 
if the women were thin as young adults. Conversely, higher recent BMI was associated with 
a reduced risk of TN breast cancer. Higher young adult BMI was associated with reduced 
risk of premenopausal ER+ cancer and each subtype of postmenopausal cancer. Higher 
WHR was associated with increased risk in pre- and postmenopausal women for all subtypes 
combined, and for ER+ in premenopausal women and TN in postmenopausal women.
There is strong evidence that recent obesity increases risk of breast cancer in 
postmenopausal women, based largely on studies of white women, with weaker evidence 
that higher BMI reduces premenopausal breast cancer risk [7]. In the few studies on breast 
cancer subtypes, the association of recent obesity appears to be stronger for hormone-
receptor positive tumors (ER+/PR+) [8,24,25]. To our knowledge, only five studies have 
been published reporting on BMI and breast cancer by hormone receptor (HR) status in AA 
women, including earlier reports from the BWHS [20], WCHS [18], and CBCS [26], which 
are included in this consortium, as well as two other case-control studies, the Women’s 
CARE Study [27] and the San Francisco Bay Area Breast Cancer Study [28,29]. Consistent 
with the present findings, the other two studies found that higher recent BMI was associated 
with lower risk of ER+/PR+ cancer in premenopausal women [28,27] and ER-/PR- cancer in 
postmenopausal women [27,29]. We also found that risk of ER+ postmenopausal breast 
cancer was only elevated for obese women who were thin during young adulthood, while 
women who were obese in both periods were not at increased risk. It is not surprising that 
this weight trajectory has the worst risk profile, given the well-established association 
between BMI and ER+ breast cancer, with obese women having reduced risk before 
menopause and increased risk after menopause. Our findings are also consistent with results 
from the multi-ethnic San Francisco Bay Area Breast Cancer Study [29] and the California 
Teachers Study Cohort, which included mostly whites [30].
Results on recent BMI and ER-/PR- tumors have been mixed and two meta-analyses found 
no significant association for pre- or postmenopausal women [8,25]. While few studies have 
evaluated these associations in AA women and results have generally been inconclusive, a 
recent meta-analysis suggested that the impact of obesity may be different in AA women 
compared to white women [25], with a stronger positive association for hormone receptor 
(HR) positive tumors (OR: 1.38; 95% CI: 1.00–1.91) and stronger inverse association (OR: 
0.73; 95% CI: 0.49–1.10) for HR negative tumors among postmenopausal AA women 
compared to white women. However, estimates were based on 4 studies among whites and 2 
among AA women.
There are few studies of recent BMI and TN breast cancer, with inconsistent results. A meta-
analysis [31] reported an increased risk for premenopausal women and no association for 
postmenopausal women, but it was based on few studies, most with small sample sizes, and 
some of the included estimates were unadjusted for any covariates. Our study is the first to 
report results separately on AA women. Our results for premenopausal women are 
consistent with an earlier report from the CBCS on basal-like tumors [32], two other case-
control studies [33,34] and a pooled analysis of 12 studies, which found non-significant 
increases in risk of TN breast cancer for premenopausal obese women [24]. For 
postmenopausal women, higher BMI was associated with lower risk of TN cancer, 
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consistent with the findings of an earlier report from the CBCS on basal-like tumors [32]. 
Three case-control studies have reported results for TN tumors in postmenopausal women, 
each based on small numbers (56–87 TN cases):one reported an OR above one [35], another 
study reported an OR below one (for basal-like tumors) [33], and the third found no 
association [36]. The Women’s Health Initiative [37] suggested elevated risk of TN breast 
cancer with higher BMI (HR: 1.37; 95% CI: 0.98–1.93), based on 307 TN cases, of which 
only 50 were AA.
Previous studies, largely in white populations, have generally reported lower breast cancer 
risk with higher BMI in early adulthood [38]. However, the few studies in AA women 
reported inconsistent results perhaps due to small sample sizes and unstable risk estimates, 
with some studies suggesting an inverse association for both pre- and postmenopausal 
women [20], for premenopausal women [27], or no association [39,40,22,28,17]. Only two 
of these, the Women’s CARE Study [27] and the San Francisco Bay Area Breast Cancer 
Study [28,29], both case-control studies, reported results by HR status. In agreement with 
our findings, these two studies suggested an inverse association for ER+/PR+ breast cancer 
in premenopausal and postmenopausal women, but risk estimates were only statistically 
significant among premenopausal women in both studies.
To our knowledge, this is the first study reporting on the association of young-adult BMI 
and TN breast cancer in premenopausal women, and we therefore cannot compare our null 
findings with other studies. For postmenopausal women, the Women’s Health Initiative [37] 
found no association with TN breast cancer (307 cases, 79% white). In the Nurses’ Health 
Study [41], there was a suggestion of an inverse association between BMI at age 18 and the 
basal-like subtype (n=226), but the confidence interval included the null and analyses were 
not stratified by menopausal status.
Because other studies reported increased risk associated with higher BMI in postmenopausal 
women to be stronger or limited to nonusers of female hormone [8,25], we repeated analyses 
excluding current users. Results in postmenopausal women remained essentially unchanged, 
which has also been reported by others [27].
The evidence for central obesity, most often measured with WHR, and breast cancer has 
been generally inconsistent for white populations, particularly for premenopausal breast 
cancer [5,42], but tends to suggest an association in postmenopausal women [7]. However, 
in two meta-analyses of studies that adjusted for BMI, the association with WHR became 
weaker and non- significant among postmenopausal women [6,7]. Although the data are 
scant, studies have suggested a distinct impact of WHR by race/ethnicity and hormone 
receptor status [42]. In agreement with our findings of increases in risk associated with high 
WHR, a recent meta-analysis reported an association between WHR and premenopausal 
breast cancer, which was stronger in AA than in white women [43]. Furthermore, the San 
Francisco Bay Area Breast Cancer Study reported elevated risk for ER+/PR+ breast cancer 
in premenopausal [28] and postmenopausal [29] AA women, albeit not statistically 
significant. Little is known about the impact of central adiposity on risk of TN breast cancer. 
Our study is consistent with the earlier finding from the CBCS including whites and AA 
women [32], suggesting elevated risk of basal-like breast cancer in premenopausal and 
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postmenopausal women. In contrast, no association with WHR for postmenopausal women 
was found in the Women’s Health Initiative [35]. Both studies adjusted for BMI.
It should be pointed out that, as in most observational studies, we used self-reported body 
size measures. However, studies have shown a strong correlation (>0.9) between self-
reported and measured weight and height [44,18,45,46], with weaker but still good 
correlation (0.74–0.93) for waist and hip circumferences [44,45,47].
The complex relationship of obesity and breast cancer has mostly been attributed to 
endogenous estrogen exposure, which varies greatly throughout life, with the major source 
being the ovaries in premenopausal women, and adipose tissue after menopause. For ER+ 
breast cancer, the inverse association found in premenopausal women has been postulated to 
be due to more frequent anovulatory cycles and faster clearance rate of free estrogens in 
obese than lean women, while, after menopause, excess adipose tissue results in increased 
estrogen production from aromatization of androgen in peripheral fat tissue [8]. In addition, 
both general obesity and central obesity are associated with elevated levels of insulin and 
insulin-like growth factor (IGF-I), chronic systemic inflammation, increased leptin, and 
oxidative stress [42]. We found that risk of TN tumors was reduced for women with a high 
BMI, but elevated for those with a body fat distribution pattern compatible with central 
obesity. While these findings need to be replicated by other studies, they support the notion 
that TN tumors may be more influenced by components of the metabolic syndrome (central 
obesity, insulin resistance, dyslipidemia, and hypertension) than by estrogens, as 
hypothesized by others [48].
Current evidence suggests that there are important differences in the association of obesity 
with overall breast cancer risk between AA and white women, which may be due, in part, to 
AA women being more likely to have ER- and TN breast cancer tumors. However, even for 
HR negative tumors, obesity appears to have a distinct impact in AA women. Important 
differences have been found between AA and white women in the relationship of BMI with 
body composition. AA women tend to have higher lean mass and lower fat than white 
women for a given BMI [49] and lower visceral adipose tissue (VAT) and higher 
subcutaneous adipose tissue (SAT) for a given amount of body fat [50] compared to white 
women. However, there is also evidence that despite less VAT, AA women are more insulin 
resistant than white women at the same level of BMI [51]. Differences in obesity-related 
circulating adipokines and inflammatory biomarkers have also been noted between AA and 
white women, with AA women having higher levels of leptin, C-reactive protein and 
interleukin-6, and lower levels of adiponectin, even after adjusting for BMI [52]. 
Furthermore, correlations between BMI and these biomarkers seemed to be stronger in AA 
than in white women in that study. Clearly, studies are needed to understand biological 
mechanisms underlying the impact of adiposity on breast cancer risk in AA women, in 
particular by HR subtypes and menopausal status.
In conclusion, effects of adiposity appear to differ by both menopausal status and breast 
cancer subtype. Further work is needed to understand the complex impact of obesity on the 
various cancer subtypes and underlying mechanisms. This is particularly important for AA 
women, given the high prevalence of general and central obesity in this population.
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